<DOC>
	<DOCNO>NCT01697605</DOCNO>
	<brief_summary>This study evaluate safety tolerability determine Maximum tolerate dose ( MTD ) and/or Recommended dose ( RD ) .</brief_summary>
	<brief_title>A Phase I Study Oral BGJ398 Asian Patients</brief_title>
	<detailed_description>This multi-center , open label , dose finding , phase I study oral single agent BGJ398 , administer continuous and/or twice daily schedule .</detailed_description>
	<criteria>Patients advance solid tumor FGFR alteration Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate organ function Patients untreated and/or symptomatic metastatic Central Nerve System ( CNS ) disease Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I , open-label , dose escalation , BGJ398 , Japanese , Asian , FGF-R</keyword>
</DOC>